[6-K] Evaxion A/S Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company focused on AI-Immunology™ powered vaccines, submitted a Form 6-K to furnish a new press release to investors. The press release, dated November 20, 2025, is titled "Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1" and is included as Exhibit 99.1. The company also states that this report is incorporated by reference into several existing registration statements on Forms S-8, F-3 and F-1.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On November 20, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit Number		Description
99.1		Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: November 20, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What did Evaxion A/S (EVAX) report in its November 2025 Form 6-K?

Evaxion A/S reported that it issued a press release titled "Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1" and furnished this release as Exhibit 99.1.

What is the focus of Evaxion A/S's press release mentioned in the Form 6-K?

The press release focuses on positive data for lead antigens in Evaxion A/S's cytomegalovirus (CMV) vaccine program EVX-V1.

How does this Form 6-K affect Evaxion A/S (EVAX) registration statements?

The Form 6-K is incorporated by reference into Evaxion A/S's existing registration statements on Form S-8 and multiple Form F-1 and Form F-3 registration statements, making the information part of those filings.

What type of company is Evaxion A/S according to the Form 6-K?

Evaxion A/S is described as a clinical-stage TechBio company that develops AI-Immunology™ powered vaccines.

Who signed the November 20, 2025 Form 6-K for Evaxion A/S?

The Form 6-K was signed on behalf of Evaxion A/S by Birgitte Rønø, who is identified as the Interim Chief Executive Officer, dated November 20, 2025.

What exhibit is attached to Evaxion A/S (EVAX) November 2025 Form 6-K?

The filing includes Exhibit 99.1, which is the press release titled "Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1".